seed
Stage
2020
Founded
2
Investors
About
NK:IO develops a novel cellular immunotherapy platform using natural killer (NK) cells to treat solid tumor cancers, initially targeting ovarian cancer. Their technology enables the production of highly potent, off-the-shelf NK cell therapies derived from umbilical cord blood stem cells, overcoming traditional manufacturing challenges.
Explore NK:IO's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.